Clinical trials: Hodgkin's Lymphoma
Breast Adenocarcinoma, Metastatic Breast Carcinoma
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma…
- Conditions
- Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT03432741
- Testing
- Belinostat, Carfilzomib, Copanlisib Hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Lymphoma
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of cyclophosphamide and filgrastim in treating patients…
- Trial name
- NCT00002501
- Testing
- filgrastim, cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 29 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
CAR-T cells have been validated effective in treating CD19 positive B cell lymphoma. Other lymphomas like Hodgkin's lymphoma and anaplastic large cell lymphoma are CD30 positive.
- Trial name
- NCT03383965
- Testing
- ICAR30 T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Immune Cell, Inc.
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Hodgkin's Lymphoma
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
MGCD0103 is an experimental drug that belongs to a class of drugs known as the histone deacetylase inhibitors, which may restore normal control in cancer cells by affecting the genes and proteins that are being made.
- Trial name
- NCT00358982
- Testing
- MGCD0103
- Where
- 5 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Mirati Therapeutics Inc.
Primary Gastric Diffuse-Large B-Cell Lymphoma
Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The optimal treatment of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) has not yet been defined. In most circumstances, a stomach-conserving approach is favored, but the role of radiotherapy is still a matter of…
- Trial name
- NCT00204659
- Testing
- Rituximab + CHOP chemotherapy
- Where
- 5 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
Non Hodgkin Lymphoma, Follicular Lymphoma
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
This is a prospective multicenter phase II pilot trial designed with the purpose of dose finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated…
- Trial name
- REAL07 (NCT00907348)
- Testing
- LR-CHOP21
- Where
- 18 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
This randomized clinical trial studies standard GVHD prophylaxis with tacrolimus and methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate in patients with hematologic malignancies undergoing…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT01951885
- Testing
- tacrolimus, methotrexate, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma, Follicular, Non-Hodgkin Lymphoma
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with…
- Trial name
- NCT01164696
- Testing
- [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Bayer
Breast Cancer, Chronic Myeloproliferative Disorders
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00651716
- Testing
- flow cytometry, laboratory biomarker analysis, Data Collection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00062114
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- 94 sites in United States
- Volunteers
- 84 people
- Sponsor
- Alliance for Clinical Trials in Oncology
B-Cell Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
Despite advancement in chemotherapy, radiotherapy and haematopoietic stem cell transplant (HSCT), and the recent introduction of more targeted therapies, a substantial proportion of patients with B-cell malignancies, such as…
- Trial name
- NCT02315118
- Testing
- T-cell therapy + Rituximab + IL-2
- Where
- Singapore
- Volunteers
- 18 people
- Sponsor
- National University Hospital, Singapore
Lymphoma
Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00017290
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, keyhole limpet hemocyanin, sargramostim
- Where
- 24 sites in United States, Canada
- Sponsor
- Genitope Corporation
NHL, Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without…
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT06119685
- Testing
- IDP-023, Rituximab, Daratumumab
- Where
- 12 sites in United States
- Volunteers
- 128 people
- Sponsor
- Indapta Therapeutics, INC.
Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma
This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma that has come back after a period of…
- Conditions
- Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma, Digestive System Signs and Symptoms, Indolent Adult Non-Hodgkin Lymphoma
- Trial name
- NCT02928510
- Testing
- Biospecimen Collection, Colonoscopy, Colposcopic Biopsy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
This phase I/II trial is studying the side effects and best dose of flavopiridol and to see how well it works in treating patients with lymphoma or multiple myeloma.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00112723
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous…
- Trial name
- NCT03075696
- Testing
- Glofitamab, Obinutuzumab, Tocilizumab
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 940 people
- Sponsor
- Hoffmann-La Roche
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Waldenström's Macroglobulinemia
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).
- Trial name
- NCT02165397
- Testing
- Ibrutinib, Rituximab
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 181 people
- Sponsor
- Pharmacyclics LLC.
Lymphoma, Nonneoplastic Condition
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV.
- Trial name
- NCT01319526
- Testing
- DNA analysis, RNA analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- AIDS Malignancy Consortium
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.